SIGLEC7: A Protein That Interacts with Sialic Acid (G27036)

Target Name: SIGLEC7

NCBI ID: G27036

SIGLEC7

SIGLEC7: A Protein That Interacts with Sialic Acid

Sialic acid-binding Ig-like lectin 7 (ISOform 3) (SIGLEC7) is a type of carbohydrate-binding protein that is expressed in various cell types in the human body. It is characterized by its ability to interact with sialic acid, which is a type of carbohydrate found on the surface of many different cell types. This interaction between SIGLEC7 and sialic acid makes it a potential drug target or biomarker for a variety of diseases.

SIGLEC7 is a member of the Ig-like family of proteins, which includes other well-known proteins such as IgG, IgM, and IgA. These proteins are responsible for providing antibodies, which are proteins that are able to bind to specific antigens and help to neutralize them. SIGLEC7 is different from these other proteins, however, in that it is specifically designed to interact with sialic acid, which is a type of carbohydrate found on the surface of many different cell types.

Sialic acid is a type of carbohydrate that is found on the surface of many different cell types, including bacteria, viruses, and cells of the body. It is made up of a single sugar molecule, which is attached to a protein called 伪-2,6-dimeric acid. This protein is able to bind to specific carbohydrates, including sialic acid, and can activate various signaling pathways within the cell.

SIGLEC7 is able to interact with sialic acid through a process called sialic acid-binding. This interaction occurs by the protein forming a covalent complex with the sialic acid. Once this complex is formed, SIGLEC7 is able to bind to the sialic acid and interact with it in a variety of ways.

One of the ways that SIGLEC7 is able to interact with sialic acid is through its ability to stimulate the production of antibodies. This is done by SIGLEC7 causing the cell to undergo a process called clonal expansion, which allows the cell to produce more copies of itself. This process is thought to be important for the immune system, as it allows the body to mount an effective response to infections and other harmful substances.

Another way that SIGLEC7 is able to interact with sialic acid is through its ability to promote the formation of tight junctions. Tight junctions are special channels that allow cells to come into close contact with one another and to exchange nutrients and other substances. SIGLEC7 is able to promote the formation of tight junctions by interacting with the protein called ZNF2, which is found on the surface of many different cell types.

SIGLEC7 is also able to interact with sialic acid through its ability to modulate the activity of various signaling pathways. For example, SIGLEC7 has been shown to be able to inhibit the activity of the pathway that is responsible for cell proliferation and survival. This is thought to be important for the regulation of cell growth and for the control of normal cell function.

SIGLEC7 is also involved in several other processes in the body, including the regulation of inflammation and the immune response. It is able to interact with sialic acid through its ability to stimulate the production of antibodies and to modulate the activity of various signaling pathways.

While SIGLEC7 is a well-established protein that is involved in many important processes in the body, its role in these processes is not yet fully understood. Further research is needed to fully determine the precise function of SIGLEC7 and to explore its potential as a drug target or biomarker.

Protein Name: Sialic Acid Binding Ig Like Lectin 7

Functions: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- and alpha-2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro)

The "SIGLEC7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets